Crossmark

Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US

Published Online: 2024-06-17

Authors

Pan, Junjie

Ren, Ning

Ren, Lanqi

Yang, YiBei

Xu, Qiaoping
License Information

Text and Data Mining valid from 2024-06-17

Version of Record valid from 2024-06-17
More Information

Article History

Received: 22 October 2023

Accepted: 7 June 2024

First Online: 17 June 2024

Competing interests

: The authors declare no competing interests.

Document is current